Keyword: Juno Therapeutics
Juno didn't immediately report CAR-T trial deaths, investors argued in a lawsuit, and now the sides have inked a $24 million settlement.
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
After ushering Juno through early fundraising, an IPO, clinical setbacks and more, CEO Hans Bishop is set for a big payday.
Novartis and Bayer executives were among a list of attendees at a private dinner in Davos with U.S. President Donald Trump.
Despite struggles in 2017, Celgene turned in 16% annual sales growth, buoyed by key drugs Revlimid, Pomalyst and Otezla.
Juno Therapeutics CEO Hans Bishop is in line for a nice payday when his company seals the deal with Celgene.
Novartis' Kymriah won regulatory milestones from the FDA and EMA as the company works to hold its leadership position in the budding CAR-T field.
Juno Therapeutics has inked a deal to use Thermo Fisher Scientific’s activation reagents in manufacturing its CAR-T therapies.
Here is some other vaccine news of note for the week.
Novartis won crucial backing for its potentially groundbreaking CAR-T drug at an FDA expert panel on Wednesday.